Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer

• DOI: 10.1056/evidoa2300144
• Publication Date: 2024-01-23T14:30:19Z
• Authors: Alfredo Carrato; Roberto Pazo-Cid; Teresa Macarulla; Javier Gallego; Paula Jiménez-Fon...; Fernando Rivera; Maria Teresa Cano; Mercedes Rodrigue...; Carles Pericay; Inmaculada Alés; Laura Layos; Begoña Graña; Vega Iranzo; Inmaculada Gallego; Rocio Garcia-Carb...; Inmaculada Ruiz d...; Carmen Guillén-Ponce; Enrique Aranda

Nab-Paclitaxel plus Gemcitabine and FOLFOXThis randomized, open-label, phase II trial compared nab-paclitaxel/gemcitabine followed by modified FOLFOX versus nab-paclitaxel/gemcitabine alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. Patients receiving nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) had a 12-month and 24-month overall survival of 55.3% and 22.4%, respectively, compared with 35.4% and 7.6% in the control group; there was a higher incidence of grade 3 or higher neutropenia and thrombocytopenia. No significant differences in febrile neutropenia, epistaxis or hemorrhage of grade 3 or higher in either group were reported. Two toxic deaths (2.6%) occurred in the experimental group.